Patent intelligence · US
US 12186285
Compositions and methods of treatment for tinea pedis
Compositions and methods of treatment for tinea pedis
Patent details — US 12186285
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 7, 2025
- Expiration
- Jan 2, 2045
- Applicant
- Compass Therapeutics LLC
- Claims
- 5
- CPC classes
- A61K, A61K31/137, A61K31/17, A61P
Quick answer
US 12186285 (Compositions and methods of treatment for tinea pedis) is held by Compass Therapeutics LLC. Status: granted. Granted Jan 7, 2025. Expires Jan 2, 2045 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Compass Therapeutics LLC
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/137, A61K31/17, A61P, A61P31/10
More from Compass Therapeutics LLC
Related pharmaceutical patents in our USPTO index.
-
US 12377112
Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
granted -
US 12312375
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
granted -
US 12286483
Method of treating cancer using CD137 antibodies and PD-1 antagonists
granted -
US 12070594
Biomedical electrode with anti-microbial properties
granted -
US 11970538
Multispecific binding constructs against checkpoint molecules and uses thereof
granted -
US 11939346
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
granted -
US 11865179
Progesterone formulations having a desirable PK profile
granted
Frequently asked questions
What is US patent 12186285?
US 12186285 (Compositions and methods of treatment for tinea pedis) is held by Compass Therapeutics LLC. Status: granted. Granted Jan 7, 2025. Expires Jan 2, 2045 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12186285?
Compass Therapeutics LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 100 pharmaceutical patents for this assignee.
When does US 12186285 expire?
Our index shows an expiration date of Jan 2, 2045 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.